The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or ...

Five therapies are currently approved by the FDA for treating the symptoms of myasthenia gravis, allowing partial to complete remission. Research suggests that five new therapies may become available ...

The FDA has approved Uplizna for generalized myasthenia gravis in adults who are anti-AChR and anti-MuSK antibody positive.

Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.

Positive topline results from two phase 3 trials reported this week may expand the treatment landscape for generalized myasthenia gravis (gMG), a rare autoimmune disease marked by debilitating muscle ...

Myasthenia gravis is a chronic autoimmune disorder that inhibits communication between nerve cells and muscles, causing muscle weakness. It has no cure, but several treatment options can help improve ...

Findings showed gefurulimab statistically significantly improved MG-ADL total score at week 26 compared with placebo. Topline data were announced from a phase 3 trial evaluating gefurulimab in adults ...

SAVANNAH, Ga. -- Inebilizumab (Uplizna) had clinically meaningful efficacy and a favorable safety profile among people with generalized myasthenia gravis (gMG), topline data from the MINT trial showed ...

Diagnosis of generalized myasthenia gravis involves clinical symptoms, serologic markers, and electrodiagnostic studies, with AChR and MuSK autoantibodies being key indicators. Differentiating ...

(RTTNews) - Amgen Inc. (AMGN) Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults with generalized myasthenia gravis, a rare autoimmune ...

Myasthenia gravis is an autoimmune condition that weakens the muscles in your body. Acetylcholine is a neurotransmitter that helps your muscles move. Most people with generalized myasthenia gravis ...

A new retrospective analysis compared clinical features of White, Hispanic, and African-American patients with MG who visited a single university-based clinic. After adjusting for covariates, the ...